XBiotech
XBIT
46 hedge funds and large institutions have $32.5M invested in XBiotech in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
143% more call options, than puts
Call options by funds: $51K | Put options by funds: $21K
128% more capital invested
Capital invested by funds: $14.2M → $32.5M (+$18.2M)
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
18% more funds holding
Funds holding: 39 → 46 (+7)
1.44% more ownership
Funds ownership: 11.69% → 13.12% (+1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$759K |
| 2 |
Millennium Management
New York
|
+$754K |
| 3 |
Goldman Sachs
New York
|
+$356K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$313K |
| 5 |
Jane Street
New York
|
+$221K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$600K |
| 2 |
Man Group
London,
United Kingdom
|
-$233K |
| 3 |
Two Sigma Investments
New York
|
-$84.4K |
| 4 |
Squarepoint
New York
|
-$75.7K |
| 5 |
Bank of New York Mellon
New York
|
-$41.5K |
XBIT Hedge Fund Activity: Q1 2024 in Review
46 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q1 2024, worth a combined $32.5M — up 128% from $14.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new XBIT positions and 3 closed out — a net gain of 7 holders — while 15 added to existing stakes and 11 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $759K. The largest seller was Morgan Stanley, cutting an estimated $600K.
- 46 institutional investors held XBiotech (XBIT) as of Q1 2024, up from 39 in Q4 2023.
- Funds reported $32.5M of XBiotech stock for Q1 2024, up 128% quarter-over-quarter.
- 10 funds opened new XBiotech positions in Q1 2024 and 3 closed out, a net change of +7 holders.
- The largest XBiotech buyer in Q1 2024 was Susquehanna International Group, an estimated $759K added.
- The largest XBiotech seller in Q1 2024 was Morgan Stanley, an estimated $600K sold.
Based on aggregated 13F filings for Q1 2024.